Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Summary

This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment. Monoclonal antibodies, such as ipilimumab and rituximab, may interfere with the ability of cancer cells to grow and spread.

Timeline

Start

2012-11-19

Primary completion

2018-03-30

Completion

2018-03-30

Drugs

Indications